The world-famous British Medical Journal Lancet has published the results of a study that ascertained the safety of Covaxin, the Bharat Biotech vaccine for coronavirus. In its latest edition, the publication said that Covaxin is capable of generating an immune response in participants.

Reacting to the report, Bharat Biotech said that it is proud about the validation from Lancet. "The findings published in the peer review journal show the safety and immunogenicity of the vaccine as seen in a double-blind, randomized trial," the pharma company said on Friday.

Suchitra Ella of BB wrote that 13,000 volunteers have been successfully administered the second dose in the Phase-3 clinical trials of Covaxin. She extended heartfelt thanks to all of them for their pro-vaccine public health volunteerism.

Rajya Sabha MP Subramanian Swamy tweeted saying, "Now that the prestigious research Journal Lancet has given kudos to Covaxin, will the Angrez ke nakli waris wake up and stop campaigning against the Swadeshi BBL in the media?"